REFERENCES


Accepted August 16, 1999.

Masao Fukuzawa 1,2 and Toshiaki Saida 2
1Department of Dermatology, Suwa Red Cross Hospital and 2Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto, 390-8621, Japan.

Topical All-trans Retinoic Acid Does not Influence Minimal Erythema Doses for UVB Light in Normal Skin

Sir,

Retinoids are used in several skin disorders, such as acne, psoriasis and ichthyoses. It is well established that retinoids interfere with epidermal proliferation (1, 2), keratinization (3) and inflammation control (4). Retinoids influence UV-induced skin changes (5). Topical all-trans retinoic acid (RA) improves photodamaged skin (5, 6).

Parallel with the therapeutic effect, topical retinoids often cause irritation, with erythema and some scaling (7). Although the irritant effect is probably not involved in the therapeutic action of retinoids, it is possible that the irritation property of all-trans RA could be, in part, accountable for some therapeutic effects (1, 7).

In this study we would like to challenge the common belief that topical retinoids enhance UV-induced inflammation. We therefore evaluated the minimal erythema dose (MED) for UVB irradiation on topical all-trans RA (tretinoin cream 0.05%) compared with vehicle cream pre-treated skin and untreated skin. The degree of erythema at different times before and after UVB irradiation was scored in the 3 different areas.

The following questions were addressed: (i) To what extent does a 7-day treatment of normal skin with all-trans RA 0.05% in its vehicle or its vehicle alone induce erythema? (ii) To what extent do these creams influence the MED for UV-B irradiation? (iii) What are the dynamics of erythema 24 and 48 h after UVB irradiation in all-trans RA pre-treated skin, vehicle pre-treated skin and untreated skin?

MATERIALS AND METHODS

The study was a single-centre, double-blind, placebo-controlled study. Approval of the Ethics Committee was obtained. A total of 15 healthy volunteers (8 men, 7 women) participated in the study. The mean age was 25 years (range 21–30 years). Their skin types were varying from type I to type III according to Fitzpatrick’s classification (8).

An area of 8 × 20 cm on the ventral upper part of one leg was treated twice daily with all-trans RA (tretinoin cream 0.05%), which is a frequently used clinical concentration, for 10 days. An area of the same size on the upper part of the other leg was treated with the vehicle of tretinoin cream (per 100 g: cremor cetomacrogolis 88 g, alcohol ketonatus 12 g and butylhydroxytolueen 40 mg) also twice daily and for 10 days. The application of both creams on the legs was selected at random and was applied in a double-blind manner. From the beginning of the application, until 4 days after the last application of the creams the volunteers were instructed to avoid sunlight exposure and not to wash the area to which the cream was applied for at least 1 h after each application.

On day 8 of treatment, irradiation of the skin was performed in 12 evaluable subjects in order to determine the MED with 3 series of 6 increasing intensities of UVB light related to the skin type of the subjects: 1 series on the all-trans RA cream pre-treated skin, 1 on the vehicle cream pre-treated skin and 1 on non-treated skin on the lateral side of the upper part of one leg. Each dose was given to a piece of skin of 4 cm². For UVB irradiation, UV21 lamps were used.

Before irradiation on days 8, 9 and 10 the skin was examined for erythema by visual scoring. The MED was defined as the lowest UVB dose that caused a distinct erythema with sharp margins over the irradiated area 24 h after irradiation. For erythema the following scale was used: 0 = no erythema; 1 = weak erythema; 2 = moderate
areas. This perifollicular pattern may be related to the actions showed a marked erythema restricted to the perifollicular while (especially all-trans RA) cream-induced erythema. UVB-induced erythema showed a diffuse erythema, however, a marked difference was found in erythema pattern can induce erythema of the skin, it might be difficult to grade the expected additive irritation or intensity of the retinoids. In: Cunliffe WJ, Miller AJ (eds.). Retinoid therapy. Lancaster 1984, MTP Press: 335–343.


Accepted August 10, 1999.

J. v. Smit, E. M. G. J. de Jong, G. J. de Jongh and P. C. M. van de Kerkhof Department of Dermatology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
E-mail: j.smit@derma.azn.nl